M&A Deal Summary |
|
|---|---|
| Date | 2025-02-19 |
| Target | Alturix |
| Sector | Life Science |
| Buyer(s) | Kelso Pharma |
| Deal Type | Add-on Acquisition |
SEARCH BY
Kelso Pharma is a business committed to bringing innovative specialty medicines to the European healthcare markets, to provide meaningful benefits to patients and create added value for healthcare stakeholders. Kelso Pharma was founded in 2022 and is based in Kelso, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| Country: United Kingdom M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-14 |
Stirling Anglian
Glasgow, United Kingdom Stirling Anglian is committed to medicines optimisation. It has sourced and developed a portfolio of medicines to help the NHS curb waste, across a range of conditions that currently place unnecessary and avoidable pressure on NHS resources. At a time when there is such pressure on the NHS to reduce costs, the company believes that it provides a real and practical solution. It works closely with stakeholders across the NHS to identify real-world problems and develop value-based solutions that support the delivery of efficient and cost-effective healthcare. |
Buy | - |
